EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase IV)Open Access · CC BY 4.0

Effectiveness and safety of an absorbable modified polymer starch powder hemostat versus usual care in gynecology procedures: A prospective, multi-center, and randomized study

Jordi Ponce, Amparo García-Tejedor iD, Marc Barahona iD, Serena Cappuccio iD, Barbara Costantini, Camilla Fedele, Lola Marti-Cardona, Giovanni Scambia

PLOS One · 2025

DOI: 10.1371/journal.pone.0331376 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, 2025. Verfasst von Jordi Ponce und 7 weiteren Autor:innen. Beteiligte Einrichtung: Gynecology Department, University Hospital of Bellvitge (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain. Hauptthemen laut MEDLINE: Starch, Hemostatics, Gynecologic Surgical Procedures. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CryoLife, Baxter Healthcare Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the safety and effectiveness of an absorbable modified polymer starch powder hemostat (AMP-SPH) compared with standard care to control hemostasis when used in adult subjects during open or laparoscopic gynecological procedures for both benign and malignant diseases.

Methods

Prospective, multi-center, randomized, and interventional phase IV study conducted on consecutive patients, aged ≥18 years, who underwent an open or laparoscopic gynecological procedure between November 2015 and July 2017 in a third-level Hospital. Study participants were randomly assigned (1:1) to receive either treatment with an AMP-SPH (AMP group) or usual standard care (SC group). The hemostatic treatment administered to the SC group was at the investigator’s discretion. The primary effectiveness endpoint of the study was the achievement of hemostasis (yes/no) within 10 minutes.

Results

Ninety patients, 44 (48.9%) in the AMP group and 46 (51.1%) in the SC group were included in the analysis. the AMP group, 97.7% (43/44) of patients achieved hemostasis as compared to the 93.5% (43/46) of subjects in the SC group (mean difference: 4.2%; 95%CI: −4.1% to 12.6%; p = .337). The time required to achieve hemostasis was lower in the AMP group (1.91 ± 1.15 minutes) than in the SC group (2.28 ± 2.09 minutes), although not significant (p = .309). A higher proportion of patients in the SC group (17.9%) was observed to require blood products compared to those in the AMP group (4.8%).A total of 29 adverse events (AEs) (24 non-serious and 5 serious AEs) were reported, 12 AEs in the AMP group and 17 in the SC group.

Conclusions

According to the results of this study, AMP-SPH was not inferior to standard care in the control of bleeding for patients undergoing gynecology procedures and the cessation of bleeding was trending to be faster with the use of AMP-SPH than with standard methods.

Trial registration

ClinicalTrials.gov NCT02835391 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

StarchHemostaticsGynecologic Surgical ProceduresHumansFemaleMiddle AgedAdultProspective StudiesPowdersAgedTreatment OutcomeHemostasis

Substanzen

StarchHemostaticsPowders

Autor:innen und Institutionen

  • Gynecology Department, University Hospital of Bellvitge (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain.
  • IDIBELL (Instituto de Investigación Biomédica de Bellvitge), Hospitalet de Llobregat, Barcelona, Spain.
  • UOC Ginecologia Oncologica, Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
  • UniCAMILLUS, International Medical University, Rome, Italy.
  • Universita' Cattolica del Sacro Cuore, Rome, Italy.

ORCID-Profile: Amparo García-Tejedor, Marc Barahona, Serena Cappuccio

Förderung

  • CryoLife
  • Baxter Healthcare Corporation

Zitieren

APA

Ponce, J., García-Tejedor, A., Barahona, M., Cappuccio, S., Costantini, B., Fedele, C., Marti-Cardona, L., & Scambia, G. (2025). Effectiveness and safety of an absorbable modified polymer starch powder hemostat versus usual care in gynecology procedures: A prospective, multi-center, and randomized study. PLOS One. https://doi.org/10.1371/journal.pone.0331376

Vancouver

Ponce J, García-Tejedor A, Barahona M, Cappuccio S, Costantini B, Fedele C, et al. Effectiveness and safety of an absorbable modified polymer starch powder hemostat versus usual care in gynecology procedures: A prospective, multi-center, and randomized study. PLOS One. 2025. doi:10.1371/journal.pone.0331376

BibTeX
@article{Ponce2025,
  author = {Ponce, Jordi and García-Tejedor, Amparo and Barahona, Marc and Cappuccio, Serena and Costantini, Barbara and Fedele, Camilla and Marti-Cardona, Lola and Scambia, Giovanni},
  title = {Effectiveness and safety of an absorbable modified polymer starch powder hemostat versus usual care in gynecology procedures: A prospective, multi-center, and randomized study},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0331376}
}
Kostenlos starten →